The analysis revealed that compared to tamoxifen, 5 years of treatment with an aromatase inhibitor reduced the 10-year breast cancer mortality by 15%.352 In addition, several randomized trials have aimed to evaluate the efficacy of ovarian function suppression (OFS) and AIs in premenopausal women. Here, CYP19A1 is linked to breast carcinoma.